Skip to main content

Table 1 The summarized characteristics of patients

From: NPM1 alternative transcripts are upregulated in acute myeloid and lymphoblastic leukemia and their expression level affects patient outcome

Disease

FAB type

Number of patients (F/M)

Age median (range)

WBC mean (range)

NPM1mut.

FLT3mut.

RUNX1/RUNX1T1

Karyotype

ddPCR-based analysis of NPM1 transcripts at the time of diagnosis

 AML

M0

1 (0/1)

64

9.7

–

–

–

NA (1)

M1

13 (7/6)

51 (25–65)

94.8 (1–310.9)

5

2

–

Aberrant (3)

NA (10)

M2

23 (8/15)

51 (19–64)

44.8 (0.5–146.4)

5

3

4

Normal (4)

Aberrant (10)

NA (41)

M3

3 (1/2)

60 (54–67)

24.8 (7.2–49.1)

1

1

–

Aberrant (2)

NA (1)

M4

13 (4/9)

52 (38–75)

51.8 (1.9–165.2)

3

2

–

Aberrant (2)

NA (11)

M5

4 (3/1)

40 (18–57)

85.6 (35.1–116)

1

1

–

Aberrant (1)

NA (3)

 ALL

ALL-B

8 (3/5)

42.5 (18–57)

17.9 (2.1–68.4)

–

–

–

Aberrant (3)

NA (5)

 AML/ALL

 

1 (1/0)

55

16.4

–

–

–

Aberrant (1)

 All patients

 

66 (27/39)

50 (18–75)

36.4 (0.5–310.9)

15 (10 exclusive)

9 (4 exclusive)

6 (4 exclusive)

Normal (4)

Aberrant (22)

NA (40)

RNA-seq-based analysis of NPM1 transcripts

 AML-T0

M1

9 (6/3)

52 (25–65)

65.1 (14.6–233)

4

1

–

Normal (1)

Aberrant (3)

NA (5)

M2

18 (7/11)

51.5 (19–64)

37.5 (1.34–146.4)

3

3

3

Aberrant (10)

NA (8)

 AML-T1

M2

1 (0/1)

64

21.7

–

–

–

NA (1)

ddPCR-based analysis of NPM1 transcripts at the three time points

 AML-T0

M1 (3), M2 (6)

9 (3/6)

52 (19–64)

59.9 (11–129.2)

2

2

2

Aberrant (5)

NA (4)

 AML-T1

M1 (1), M2 (8)

9 (3/6)

56 (20–64)

17.9 (2.3–35.4)

–

–

–

NA (9)

 AML-T2

M1 (3), M2 (4)

7 (4/3)

54 (20–65)

15.9 (6.6–29.9)

2

–

1

NA (7)

  1. FLT3 mut. FLT3-ITD (internal tandem duplication in the FLT3 gene), RUNX1/RUNX1T fusion gene, result of t(8;21) translocation, NA data not available, AML-T0 AML at the time of first diagnosis, AML-T1 AML after therapy, AML-T2 AML at the relapse